Key takeaway: Suraksha Diagnostic Limited's investor presentation detailed the company's financial performance for Q1 FY27, reporting revenue from operations of INR 876.5 million, a year-on-year growth of 28%. The EBITDA was INR 315.3 million with a margin of 36.0%, while the profit after tax (PAT) reached INR 128.5 million, reflecting a 40% increase compared to the previous year. Management highlighted the expansion of their network, with new hubs and spoke centers launched in West Bengal and Jharkhand. Suraksha Genomics showed significant growth, with revenue increasing by 136% year-on-year. The presentation emphasized the company's commitment to enhancing diagnostic services and expanding its footprint in Eastern and North-Eastern India, leveraging technology and strategic partnerships to drive future growth.

Key takeaway: Suraksha Diagnostic Limited held its earnings conference call on May 22, 2026, to discuss its financial results for Q4 and FY26. Management reported a strong performance, with revenue from operations reaching INR 3,104.1 million, a year-on-year growth of 23.1%. The company emphasized its expansion in genomics and molecular diagnostics, including a partnership with IIT Kharagpur for AI-driven Alzheimer's detection. Suraksha introduced advanced technologies in its facilities, such as a helium-free MRI system, and launched specialized clinics. The financial highlights included an EBITDA margin of 31.73% and a profit after tax of INR 314 million. Management noted the challenges of new center ramp-ups affecting margins but expressed confidence in future profitability as these centers mature. The company plans to continue expanding its footprint in eastern India and enhance its service offerings.

Key takeaway: Suraksha Diagnostic Limited reported a strong financial performance for FY26, with a 23% year-on-year revenue growth, driven by the core diagnostics business and the expansion of new centers. Management highlighted a 26% increase in Q4 EBITDA to ₹252 million, despite ongoing investments impacting margins. The company added 20 centers since its listing in December 2024, focusing on growth in Eastern and North-Eastern India. Key financial metrics included a total income of ₹3,104 million for FY26 and a PAT of ₹314 million, reflecting a 1% increase from FY25. The presentation also detailed strategic initiatives, including the launch of Suraksha Genomics and the acquisition of Fetomat Wellness, aimed at enhancing service offerings and market position. Management emphasized operational efficiency and customer service as priorities for future growth.

Key takeaway: Suraksha Diagnostic Limited held its Q3 and nine-month FY '26 earnings conference call on February 6, 2026. Management reported a 30% year-on-year revenue growth for the quarter, driven by volume expansion and the introduction of genomic testing. EBITDA margins experienced temporary compression due to pre-operative costs associated with new centers, but management emphasized the efficiency of established centers. The company has commissioned 12 new centers and is in the process of opening six more. Management highlighted the positive market response to its genomics vertical, Suraksha Sutra, and noted ongoing collaborations with leading infertility chains. Financially, total income for Q3 reached INR 783.09 million, with a PAT of INR 72.41 million. The company aims to expand its center network and improve margins as new centers mature. Management reiterated its commitment to long-term growth despite short-term margin pressures.

Key takeaway: Suraksha Diagnostic Limited's investor presentation highlighted strong financial performance for Q3 and the nine-month period ending December 31, 2025, with a 30% year-over-year revenue increase and a 22% growth for the nine-month period. Management reported that the expansion plan is progressing well, with 12 centers operational and 6 under development. EBITDA experienced a planned marginal compression due to pre-operative expenses for new centers, while the core business maintained a robust 37% EBITDA margin. The presentation emphasized the positive market reception of the 'Suraksha Sutra' genomics vertical, which has established a significant first-mover advantage in Eastern India. Management stated a commitment to investing for long-term growth, aiming to deliver value to shareholders. The document also outlined strategic expansion plans and the integration of advanced technologies in diagnostics.